Method of animal hepatosis treatment and prevention

FIELD: medicine, veterinary science.

SUBSTANCE: method involves injections to animals of hepatic tissues hydrolysate and mineral salts of isotonic concentration in effective doses.

EFFECT: method allows reducing disease incidence, improving safety of livestock, increasing effectiveness and reducing treatment time.

4 cl, 5 tbl, 5 ex

 

The invention relates to medicine, namely to veterinary medicine, and can be used for the treatment and prevention of liver diseases of animals.

It is known that in veterinary medicine in the treatment of intoxication, dyspepsia and anemia animals injected intramuscularly and subcutaneously 1-2 times daily solutions of hydrolysates of blood in doses: calves 40,0-150,0 ml; pigs-will 10,0-40,0 ml, treatment - 3-4 days ("Veterinary encyclopedia," edited by K. Skryabin. "Soviet encyclopedia". M., 1969. S-422). Apply hydrolysates blood (protein products of the hydrolytic breakdown of proteins), which belong to the group of blood fluids, because they perform one of the functions of transfused blood is a function of parenteral protein nutrition. In addition, the hydrolysates of blood have active proteotoxic action. In the treatment of animals by solutions of hydrolysates blood heal not only the various forms of anemia, but also normalize regenerative hematopoiesis. However, the known method of treatment of intoxication and dyspepsia using solutions of hydrolysates blood is unable to provide curative and preventive effect on the health of the liver.

Now the actual problem is the safety of growing and adult animals with liver disease. The relevance of this PR the problems currently associated with the in animal breeding in Russia, including in the Kuban, progresses waste growing and productive adult animals (V. Antipov, Menshenin CENTURIES, Gurchenko A.N. and other Effective treatment technologies for increasing reproduction, preservation, and animal productivity (HOWTO). Krasnodar, 2005. C.1, 42-43) due to liver disease, namely, hepatosis. The hepatosis are liver disease, dystrophic (fat, protein and toxic degeneration, the amyloidosis, cirrhosis) and functional failure. In the Genesis of liver disease, for example, ruminants (cows) have physiological and genetic predisposition highly productive cows to pathological mobilization of the reserves of its own body for dairy products, which in turn leads to excessive fat, and subsequently protein and toxic liver dystrophy.

There is a method of treatment heptonic diseases using drugs, administered to the animals by injection subcutaneously, intramuscularly or intravenously according to standard techniques. To well-known drugs used for the provision of medical care for heptonic diseases include: glucose, gemodez, methionine, tocopherol, analgin, urotropine and cholagogue (V. Antipov, Menshenin CENTURIES, Gurchenko A.N. and other Effective zooveterinary the s technologies to improve reproduction, the safety and productivity of animals (HOWTO). Krasnodar, 2005. C.1, 42-43). However, these drugs are aimed at eliminating toxins from the body, bile from the liver of the patient, pain relief, but they do not restore the structure and function of the liver.

Messages in the patent and periodical literature about methods of treatment and prevention, and medical treatment for hepatosis in animals that restore the structure and function of the liver, we have not identified.

Object of the invention is the preservation and enhancement of productivity of animals.

Technical result provided by the invention, is to reduce morbidity, improve livability, efficiency and the reduction of treatment time with the help of effective therapeutic and preventive tool.

Technical essence is achieved by the fact that in the known method of treatment of hepatosis in animals comprising the administration of a medicinal product by injection subcutaneously, intramuscularly or intravenously, according to the present invention is administered one injection per day of solution of the hydrolyzate of the tissues of the liver and mineral salts isotonic concentration: therapeutic purposes for 5-6 days in a row - cows weighing 350-550 kg dose 20,0-40,0 ml, and calves before the TLD is months of age at a dose of 10.0 to 12.0 ml, and enter 0.5 dose subcutaneously and 0.5 dose intramuscularly at the same time, critical animals intravenously at a dose of 100.0-200.0 ml in dilution 1:1 with 40%glucose; prevention - cows weighing 350-550 kg dose of 10.0 to 20.0 ml every 7-10 days, only 5-6 injection.

The novelty of the proposed method for the treatment and prevention of hepatosis in animals due to the fact that the method is carried out with a solution of the hydrolyzate of the tissues of the liver and mineral salts isotonic concentration, the pH of which is 5,7-7,0, which has a therapeutic effect on the cells of hepatocytes, which does not happen when using other protein hydrolysates (blood, spleen, etc.

Injection method for the treatment and prevention of hepatosis animals used in connection with the fact that when liver disease entering treatment-and-prophylactic means in conjunction with the food and the absorption of its will be ineffective because the digestive characteristics of ruminant animals, besides a sick animal, as a rule, no appetite. As for the digestive characteristics of ruminant animals (cows, sheep, goats, camels etc), received in the digestive system solution treatment and prophylactic substances containing amino acids, including essential, can be used by the body as a nutrient medium, in addition, it is impossible to accurately control the th dose received drugs in the body together with the food. Injections of a solution of the hydrolyzate of the liver promotes faster and better difundieran (penetration) in the liver than when taking it with food, resulting in more active are regenerative processes and linking toxic substances.

Injection solution individually for each animal allows you to evaluate its condition, to adjust the dose (to apply it in a smaller amount) and the duration of treatment.

Therapeutic tool for the treatment of hepatosis animals receive the following way: for disaggregation chopped liver tissue incubated in enzyme solution and weak solution of hydrochloric acid. The suspension obtained by repeated pipetting, washed by centrifugation. Received centrifugal includes the following amino acids: tryptophan, histidine, lysine, leucine, threonine, methionine, isoleucine, valine, phenylalanine, alanine, arginine, aspartic acid, glutamic acid and aminouksusnoy acid. Then with this tool, containing amino acids, including essential, introducing mineral salts to isotonic solution concentration (sodium disulfit, magnesium oxide, sodium chloride, potassium hydroxide, sodium acetate, glucose and water for injection, and the pH value should is from 5.7 to 7.0.

When the hydrolytic cleavage of the protein structures of liver extract, rupture of long polypeptide chains of the protein to amino acids. In the process of splitting a protein loses its species specificity, colloidal properties and already possesses neither the primary toxic or antigenic and anaphylactic properties.

The advantage of the drug is that it consists of amino acids liver tissue, and therefore enters into the body by injection method allows you to selectively direct the drug to the liver, as in the body there is the adjusted relationship of the endocrine system.

The method of treatment and therapeutic efficacy of the means was tested on imported livestock of cattle.

Example 1. The method of treatment and therapeutic effectiveness of the tool was tested on imported livestock cattle with signs of fatty degeneration after calving (21.05.2007, 28.05.2007, in conditions of farms LLC AF "open space" Slavic district of Krasnodar region. Using percussion [Smirnov, A.M., Konopelko AP, Postnikov V.S., and other Clinical diagnosis of internal non-infectious diseases of farm animals. HP: Kolos, 1981. S-258] were ibrani 19 fresh cows with increased border of liver dullness and divided into two groups: experienced (10 goals) and control (9 goals). Sick animals of the control group did not enter any drugs. Animals of the experimental group was administered a single injection of therapeutic and preventive tool in the day for 6 consecutive days at a dose of 10 ml subcutaneously (s/C) and 10 ml intramuscularly (I/m) at the same time. Parallel to the experimental and control animals (table 1) were treated milk production. The results of the experiment are summarized in table 1.

Table 1
Dairy products and liver condition before and after treatment.
date of calvingsize
liver, cm
dose ml
21-22.05.07
milk yield, l
22.05.07
dose ml
23.05.07
milk yield, l
23.05.07
dose ml
24-26.05.07
size
liver, cm
milk yield, l
28.05.07
experienced group
20.05.0723,010+1017,7510+1016,510+1014,5
20.05.07a 21.510+1020,510+1013,8510+1014,020,8
17.05.0723,510+10of 18.7510+1023,510+1013,026,75
19.05.0718,010+1019,7510+1022,0510+1011,022,8
17.05.0719,010+1018,010+1024,610+1011,524,1
15.05.0725,010+1014,010+1022,6 10+1013,021,35
18.05.0715,010+1017,2510+1028,410+1015,530,0
18.05.0721,010+10of 17.010+1024,7510+109,025,25
17.05.0723,010+1015,010+1019,510+1012,525,5
18.05.0716,510+10was 12.7510+1020,610+109,025,25
srsac.20,552017,08 2021,642012,324,13
the control group
18.05.0715,5-5,9-4,8-13,08,15
20.05.0716,0-4,85-3,45-14,04,3
17.05.0715,0-16,95-19,8-12,519,75
18.05.0718,0-12,5-15,65-16,017,8
19.05.07 16,0-14,35-at 11.25-13,015,5
18.05.07of 17.5-7,25-9,5-15,511,5
17.05.0725,0-in/slaughter-----
18.05.0715,0-15,0-22,75-to 12.0a 21.5
18.05.0719,5-8,55-11,85-13,016,6
srsac.of 17.5-10,67-12,38-13,6314,39

Based on data from table 1 the average value of diagnostic measurements of percussion borders on a horizontal line according to Aliyev [Aliev, A.A. Operational research methods of farm animals. Leningrad: Nauka, 1974. S-236] in the experimental group before treatment therapeutic and prophylactic agent was 20,55 see After the treatment tool 6 days linear measurements of the liver was 12.3 see In the control group, the linear size of the liver was slightly changed.

Therapeutic efficacy of the method and means has resulted in increasing the productivity and reducing the size of the topographic field the area of liver dullness in all observed cows from the experimental group, and the difference between the defined indicators was significant in favor of fresh animals compared to the control. Results clinical observations have shown positive dynamics of recovery of the liver and dairy productivity in critical for cows post-calving. During this period, milk yield experimental animals raised up (4 kg each control is inoe milking), while in the control group yields increased two times less (2 kg). The difference between the groups regarding milk production, apparently, was due to the different functionality to manage metabolic processes: the cows of the experimental group in this period of lactation might make better use of the nutrients obtained from food than cows in the control group. The first of them in the period of milking less use of reserves in the body, less "devalis" and therefore kept higher milk yield in this period of lactation. Reduced milk production by the cows of the control group in early lactation due to the fact that they lacked energy in the slow adaptation of the organism to the use of feed nutrients to replace their reserves.

Example 2. The study of therapeutic efficacy of the method and therapeutic means were carried out at JSC "Precepts of Ilyich" Leningrad district, Krasnodar Krai, 21.06.2007 on 25.06.2007 Board imported livestock cattle with signs of General exhaustion and Suleimaniya"that pointed to the forced culling. The trial was carried out on fresh cows live weight 350-550 kg Method and dose of treatment-and-prophylactic picked up depending on the severity of the disease, the appearance of the animal (total exhaustion, atony of the rumen and signs "suleimania"). The injection was done once a day for 5 days the results of the experiment are summarized in table 2.

110-290 ml
Table 2
Information about the clinical status of cows before and after treatment.
date of calvingthe liver size, cmsostrataforecastdose ml
21-24.06.07
the liver size, cmsostrataforecast
21.06.0719,0atonynegative.200+30+20+20+209,0Hypo.benefits.
16.06.0725,0atonyAstor.30+20+20+20+208,0Normabenefits.
13.06.0726,0atonyAstor 30+30+20+20+2011,0Hypo.benefits.
6.08.0622,0atonyAstor.35+20+20+20+20to 12.0Hypo.benefits.
5.05.0714,0atonynegative.20+20+220+20+209"0Hypo.benefits.
17.10.0628,0atonybenefits.30+20+20+20+2013,5Hypo.benefits.
7.10.0618,0atonynegative.30+20+40+20+209,5Hypo.benefits.
srsac.21,7110,2

The data in table 2 show that, despite the different clinical condition and prognosis, the liver after treatment regained their anatomical size, and General condition and function of the rumen of cows has improved, and they were not sent culling.

Example 3. Therapeutic efficacy of ways and means was carried out on imported livestock in the SEC "Precepts of Ilyich" Azov district of Rostov region. In the economy through 1-1,5 months after calving was observed loss of livestock and averaged 7-10 goals in the month. Due to repeated opening of the fallen cows diagnosed pathological degeneration of the liver, up to cirrhosis. The experiment was conducted on 8 cows (3 fresh and 5 with lactation 4-5 months), with clinical signs of cachexia, increased liver, atony of the rumen (six goals) and hypotension scar (three cows) with a poor prognosis. Method and dose of treatment-and-prophylactic picked up depending on the severity of the disease. Data calving, the parameters of the overall condition and dimensions of the liver before and after testing are shown in table 3.

13,13 cm
Table 3
Information about the Kli the practical condition of cows before and after treatment.
date of calvingthe liver sizesostrataforecastdose ml
4-8.07.07
the liver sizecomp.
scar
forecast
1.01.0719 cmatonynegative.40+200+40+20+2014 cmNormabenefits.
23.06.0726 cmatonynegative.40+200+40+20+2013.5 cmNormabenefits.
3.05.0723 cmHypo.negative.40+20+40+20+2010.5 cmNormabenefits.
3.05.0720 cmatonynegative.40+20+20+20+20 13 cmNormabenefits.
4.02.0721 cmHypo.negative.40+20+20+20+2014.5 cmNormabenefits.
21.02.0721 cmatonynegative.40+20+40+20+2010.5 cmNormabenefits.
18.05.0727 cmatonynegative.200+20+20+20+2015 cmNormabenefits.
17.01.0720 cmatonynegative.200+200+200+20014 cmNormabenefits.
srsac.21,13 cm120-800 ml

Data in table 3 confirm the effective dynamics of the treatment of cows with hypertrophied liver offer therapeutic and prophylactic agent, although the treatment regimens and the use of different doses were associated with the overall clinical condition of the animals, who were threatened with death. The effectiveness of the method confirms the insertion of the intravenous dose of 200 ml, as it allows a shorter time to revive the animal.

Example 4. Check the efficiency of the method and therapeutic properties of the proposed tool was carried out on calves belonging LLC Agroholding "Avida" Stary Oskol district of Belgorod region. The farm was observed mortality of calves. The diagnosis of toxic diarrhea degeneration of the liver was revealed as a result of the repeated Commission of the opening, and also on the basis of history and clinical picture. Dissection was performed no earlier than 2 hours from disease. Liver on autopsy was yellow or gray-yellow (clay) color, the feel is moderately dense or loose. In most cases, palpation of the liver, some areas were razdavlivanii in the hand or showed various size parts broken liver tissue. Often found kidney clay color with light soft surface is Yu cortical layer. During the dissection of the blood was not curtailed. The mucous membrane of the intestines, diffuse or on individual sections of inflamed, bright red, swollen, sometimes covered with a transparent viscous mucus, sometimes with noticeable small hemorrhages. In severe cases, on the mucous membrane were visible erosion and ulcers. Often in the rumen showed the presence of casein concretions.

In the control group calves, depending on the General condition and character of bowel movements, physiological, and hypertonic solutions were injected subcutaneously (s/C) or intravenous (IV), the ratio of their purposes also varied from once to three times a day. The medical complex, which was used in the household consisted of the following: glucose; NaCl solution; solution of ringer-Locke; calcium borogluconate; tetravit or tetramer; polyvalent antitoxic serum or any polyvalent serum. Tetravit or tetramer used 1 injection subcutaneously (s/C) or intramuscularly (I/m) on the course of treatment; polyvalent serum was administered I/m 1 time per day during treatment. In addition to drug treatments observed half-starved feeding regime to recovery, and then gradually increased milk quota to normal within 4-5 days.

Calves from the experimental group used our method and treatment. Injection is the Oia did 1 time per day, the amount of applicable funds amounted to one introduction 10-12 ml, with 0.5 dose was administered I/m, and the second dose of 0.5 - p/K. In the course of medical treatment was reduced to three days, Topographic boundaries of the location of the liver after treatment decreased two times. The main symptom of toxic diarrhea, even in the presence of impurities in the blood and liquid faeces, after the second day of treatment disappeared, and consistency of feces normal, what the data indicates (table 4).

td align="center"> 10.5 cm
Table 4
Information on the treatment of toxic liver dystrophy and diarrhoea in calves at the dairy complex LLC Agroholding "Avida".
date born.weight p/R.date treatmentthe clinically. symptomthe liver sizedose 6+6 mlthe clinically. symptomdose 5+5 mlthe liver size
experienced group
22.04.0638 kg 8.05.06diarrhea10.5 cm1-3 dayresolvedday 45.0 cm
24.04.0638 kg11.05.05diarrhea10.0 cm1-3 dayresolved4-6 day5.5 cm
27.04.0637 kg11.05.06diarrhea11.0 cm1-3 dayresolved4-5 day6.0 cm
30.04.0633 kg12.05.06diarrhea9.5 cm1-3 dayresolved4-6 day 5.0 cm
3.05.0633 kg12.05.06diarrhea10.5 cm1-3 dayresolvedday 45.5 cm
4.05.0632 kg13.05.06diarrhea10.5 cm1-3 dayresolvedday 45.5 cm
2.05.0630 kg12.05.06diarrhea9.0 cm1-3 dayresolvedday 45.0 cm
4.05.0634 kg12.05.06diarrhea10.0 cm1-3 day resolvedday 45.0 cm
5.05.0633 kg12.05.06diarrhea10.5 cm1-3 dayresolved-5.5 cm
6.05.0634 kg9.05.06diarrhea10.0 cm1-2 dayresolved4-5 day5.0 cm
8.05.0634 kg16.05.06diarrhea9.0 cm1-2 dayresolved-5.0 cm
9.05.0633 kg10.05.06diarrhea1-3 dayresolved4-5 day5.0 cm
26.04.0636 kg12.05.06diarrhea11.5 cm1-3 dayresolved4-6 day6.5 cm
26.04.0636 kg12.04.06diarrhea10.0 cm1-3 dayresolved4-5 day5.5 cm
27.04.0635 kg11.05.06diarrhea10.5 cm1-3 dayresolved4-6 day6.0 cm
28.04.0638 kg/td> 1.05.06diarrhea9.0 cm1-3 dayresolved4-5 day5.0 cm
6.05.0630 kg9.05.06diarrhea9.0 cm1-3 dayresolved-5.0 cm
11.05.0631 kg13.05.06diarrhea9.0 cm1-3 dayresolved-5.0 cm
12.05.0630 kg13.05.05diarrhea9.5 cm1-3 dayresolvedday 4 5.0 cm
12.05.0630 kg14.04.06diarrhea10.0 cm1-3 dayresolvedday 45.0 cm
average9,98 cmaverage5.3 cm
the control group
date born.weight p/R.the clinically. symptomdate treatmentdays Leche.date casePat. diagnosis
14.03.0630 kgdiarrhea20.03.06, 19-21.04.06422.04.06steatosis
18.03.0629 kgdiarrhea20.03.06, 19-21.04.06,28-29.04.06630.04.06steatosis
9.04.0633 kgdiarrhea20-21.04.06228.04.06steatosis
20.04.0637 kgdiarrhea21-22.04.06,1-4.05.0664.05.06steatosis
25.04.0638 kgdiarrhea28-30.04.06310.05.06steatosis
1.05.0631 kgdia is nl 3-4.05.06,9-11.05.06520.05.06steatosis
18.02.0638 kgdiarrhea20.03.06,29-30.04.06, 1-4.05.06712.04.06steatosis
3.03.0627 kgdiarrhea20.03.06,28-29.04.0634.05.06steatosis
18.03.0626 kgdiarrhea20.03.06,20-21.04.0637.06.06steatosis
1.04.0631 kgdiarrhea20.04.06,20-21.04.062 24.04.06steatosis
6.04.0636 kgdiarrhea20.04.06,20-21.04.06225.04.06steatosis
10.04.0633 kgdiarrhea20.04.06,20-21.04.06,28-30.04.0641.05.06steatosis
13.04.0637 kgdiarrhea20.04.06,20-21.04.06226.04.06steatosis
22.04.0636 kgdiarrhea1-4.05.06410.06.06steatosis
22.0406 36 kgdiarrhea20.04.06,1-4.05.06510.05.06steatosis
23.04.0637 kgdiarrhea2-4.05.0636.05.06steatosis
24.04.0636 kgdiarrhea2-4.05.06314.06.06steatosis
25.04.0636 kgdiarrhea26.04.06,28-29.04.0639.05.06steatosis
29.04.0635 kgdiarrhea 2-4.05.06,6.05.06417.06.06steatosis
3.05.0630 kgdiarrhea3-4.05.06,6.05.06314.05.06steatosis

The proposed method for the treatment of experimental calves, not only proved when Troubleshooting symptoms and causes of dehydration, but also noted a high safety of the calves. If you look at the treatment of the calves of the control group according to the scheme used in the household, it may be noted that some of the calves was noted that particular effect recovery of the General condition, but ultimately, all calves subsequently died with a diagnosis of steatosis, because none of the prescribed drugs was not a direct hepatic tool.

Example 5. Test method and means for prophylactic purpose was carried out on imported livestock of cattle in the amount of 10 goals in terms of economy SPK them. Kalinin Azov district of Rostov region. Experimental animals did six injections treatment-and-prophylactic means, with chickens the treatment has been explored by one injection every seven days.

Table 5
The clinical condition of the animals before and after prophylaxis.
sostratathe liver sizedose (ml) 2, 9, 16, 23, 30.06.07date calvingthe liver sizesostrata
Hypo.17.5 cm10+10+10+10+10+1030.06.079 cmNorma
atony17 cm10+10+10+10+10+102.07.0710 cmNorma
Hypo.15 cm10+10+10+10+10+103.07.079 cmNorma
atony16.5 cm10+10+10+10+10+103.07.079.5 cmNorma
atony 17.5 cm10+10+10+10+10+107.07.0710.5 cmNorma
atony18 cm10+10+10+10+10+108.07.0710 cmNorma
Hypo.14 cm10+10+10+10+10+108.07.079 cmNorma
Hypo.13 cm10+10+10+10+10+109.07.079 cmNorma
atony15 cm10+10+10+10+10+1016.07.079 cmNorma
atony16 CM10+10+10+10+10+1016.07.079 cmNorma
srsac.14,38 cm10×6 = 60 ml9, cm

The results of table 5 show the most efficient and economical use of funds with the preventive purpose. The dose of the drug was only 10 ml, while in cows after calving was not observed in the clinic adipose hypertrophy of the liver and symptoms of exhaustion, and the scar was assessed as "normal". The use of funds under this scheme allows to obtain healthy young animals, to avoid complications (gynecological diseases) and fatty liver, which subsequently cause mass departure (death or forced slaughter) high-yield imported cattle.

As seen from the above examples, the scheme and the dose of the drug use for the above cases are selected depending on the particular case, the severity of the disease, the type of animal and the special conditions of each farm. For example, the minimum dose for a cow weighing 350-550 kg 10.0 ml prevention. Newborn calves and calves at two months of age the average dose of 10.0 to 12.0 ml, while imposing a 0.5 dose subcutaneously and intramuscularly with 0.5 at the same time. Fresh cows who have hepatic changes occur with concomitant changes in peristalsis predzheludkov, the total depletion and metabolism, doses of the drug can be 20,0-40,0 ml subcutaneously and intramuscularly at the same time. When the maternity paresis and critical animals, with clear signs of Suleimaniya and avoid forced slaughter, the drug is administered intravenously at a dose of 100-200 ml in dilution 1:1 with 40% glucose. It should be noted that despite the different status of animals (fatty degeneration, total exhaustion, suleimania, cirrhosis, chronic diarrhea and liver dystrophy), therapeutic drug has a constant composition of the components and their quantitative relationship to each other is not changed.

Thus, studies have shown that the proposed method for the treatment and prevention of hepatosis in animals with a solution of the hydrolyzate of the tissues of the liver and mineral salts isotonic concentration can reduce morbidity, to enhance the security of the population, to increase the efficiency and reduce the time of treatment.

1. Method for the treatment and prevention of hepatosis cattle, comprising the administration of a medicinal product by injection subcutaneously, intramuscularly or intravenously, characterized in that as a drug used solution of hydrolyzed liver tissues and mineral salts isotonic concentration, which is injected once a day.

2. Method for the treatment and prevention of hepatosis cattle according to claim 1, characterized in that with the medical purpose for 5-6 day is consecutive to the cows at a dose of 20-40 ml, and calves at a dose of 10-12 ml of injected solution of the hydrolyzate of the tissues of the liver and mineral salts in the isotonic concentration, and 0.5 dose injected subcutaneously with 0.5 dose intramuscularly.

3. Method for the treatment and prevention of hepatosis cattle according to claim 1, characterized in that critical animal solution of the hydrolyzate of the tissues of the liver and mineral salts in the isotonic concentration of the injected dose of 100-200 ml in dilution 1:1 with 40%glucose.

4. Method for the treatment and prevention of hepatosis cattle according to claim 1, characterized in that the cows for the prevention introduce a solution of the hydrolyzate of the tissues of the liver and mineral salts in isotonic concentrations in a dose of 10-20 ml every 7-10 days, only 5-6 injections.



 

Same patents:

FIELD: veterinary science.

SUBSTANCE: invention refers to veterinary science, particularly to agents and methods of treating keratoconjunctivitis in cattle. A preparation for treatment and prevention of infectious keratoconjunctivitis in cattle contains an aqueous solution of Sulfur, Echinacea purpurea, Hepar sulphur, Belladonna albus, Apis melifelica and tissue nosode in the following relation, wt %: Belladonna albus C6 - 10, Sulfur C6 - 20, Echinacea purpurea C6 - 10, Apis melifelica C6 - 30, Hepar sulphur C6 - 15, tissue nosode D6 - 15. The method for treatment and prevention of infectious keratoconjunctivitis in cattle involves intramuscular introduction of said preparation to calves, cows and heifers once a day every 3-5 days, and to calves to 80 kg of live weight the preparation is introduced in a dose 1-2 ml/10-15 kg of live weight, and to cows and heifers in a dose 1-2 ml/100 kg of live weight.

EFFECT: preparation and method exhibit high therapeutic efficiency in comparison with analogues.

4 cl, 4 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and namely to hepatology and biotechnology, and deals with treatment of chronic diffusion liver diseases as well as treatment of liver cirrhosis and portal hypertension by means of the biotransplant (BT) obtained for that purpose. BT contains mixed cell pool in which 40% comprise stem cells, including stromal mesenchymal and hepatocyte bipotent stem cells, and the rest 60% - progenitor cells in the various phase of differentiation, including new immature hepatoblasts and progenitor cells of erythroid row, hemopoietic cells. Mixed BT cell pool is characterised with the expression of the following surface markers: CD13, CD29, CD44, CD90, CD117 (c-Kit) and absence of CD34 expression. For the purpose of treatment there injected is the above BT in the form of suspension in physiological solution in quantity of 2-4 mln cells per 1 kg of the patient's weight. At liver cirrhosis and portal hypertension, BT is injected in the form of suspension in physiological solution at total number of BT cells of 350 to 500 mln.

EFFECT: BT injection given above is an independent treatment method of liver diseases, which provides stable decrease of the process activity, decrease of degenerative dystrophic changes, and recurrence-free period of 12 months long.

3 cl, 3 ex, 9 tbl, 12 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns biopharmaceutics and PEG conjugates of natural or recombinant urate oxidase (uricase). Uricase is bound covalently to poly(ethylene glycol) or poly(ethylene oxide) (both denoted as PEG), with average of 2 to 10 PEG threads are conjugated with each uricase sub-unit, and average molecular weight of PEG is approximately between 5 kDa and 100 kDa.

EFFECT: obtaining almost non-immunogenic PEG uricase conjugates preserving at least 75% of uricolytic activity of non-modified enzyme.

44 cl, 12 ex, 17 dwg

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology, in particular to hepatic cells production, and may be used in medical science. From the whole liver or resected part thereof, a cell population enriched with living cells of human liver, including hepatic stem cells/precursor cells, is obtained. Cell population contains functional hepatocytes and biliary cells expressing cytokeratin 19 (CK19), but not expressing albumin, as well as hepatic stem cells/precursor cells 9 to 13 mcm in diameter and expressing EP-CAM, CD 133 markers. Resulting cell population is used for hepatotherapy.

EFFECT: production of living population of hepatic cells sufficiently efficient for regeneration.

60 cl, 16 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, to gynecology in particular. It is designated for optimization of venter metriosis patients treatments in clinical trial. For this purpose patients of the reproductive age intake "Skvaakan" in addition to a hormonal medicine. The intake is implemented intramuscularly, 2.0 ml per day during 75 days with septan interruption after each 30 days. This method contributes to reduction of treatment terms, disease backsets, reactivation of reproductive function among the patients of this category.

EFFECT: reduction of treatment terms, disease backsets, reactivation of reproductive function.

3 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to human stem hepatocytes. Offered composition includes primitive human stem hepatocytes expressing Ep-CAM, AC 133 and albumin, and culture medium. These primitive human stem hepatocytes are precursors of proximal stem hepatocytes that are precursors of hepatocytes or precursors of bile ducts. Offered method of human cells liver-tissue precursors release includes identification of cells expressing Ep-CAM, AC 133 and albumin. Offered method of human hepatocytes precursors released by method under cl.15 or 16, cells precursors are primitive human stem hepatocytes expressing Ep-CAM, AC 133 and albumin. Offered method of human liver-tissue hepatocytes precursors release includes identification of cells expressing Ep-CAM. Offered method implies primitive human stem hepatocytes release expressing Ep-CAM, AC 133 and albumin. Offered primitive human stem hepatocytes expressing Ep-CAM, AC 133 and albumin released by method under cl. 26. Offered method implies proximal human stem hepatocytes release. Offered method provides treatment of liver dysfunction and diseases including introduction of primitive human stem hepatocytes in effective amount. Released primitive human stem hepatocytes are offered.

EFFECT: invention enables to apply produced compositions for cell therapy and bioartificial organs.

59 cl, 11 ex, 4 tbl, 20 dwg

FIELD: medicine.

SUBSTANCE: it has been suggested the method for introducing a preparation in efficient dosage being either a substance or preparation prepared according to homeopathic technique or biologically active additive that contains a substance isolated out of hepatic cells being slightly hydrophobic, water-soluble, negatively charged at alkaline pH, at molecular weight ranged 500-15000 Da that enables to decrease tissue-specifically the ratio of phosphorylated adenosine diphosphate against the quantity of atomic oxygen spent by highly energized mitochondria in the course of oxidizing phosphorylation. The suggested method and preparation enable to treat efficiently astheno-depressive state and, also, increases the efficiency of complex therapy of pulmonary and intestinal diseases.

EFFECT: higher efficiency of therapy.

16 cl, 21 ex

FIELD: medicine.

SUBSTANCE: method involves per os administering Hepatosan at a dose of 0.8 g/day. The total treatment course is 2 months long.

EFFECT: high activity of 7-α hydroxylase; no adverse side effects observed.

3 tbl

FIELD: medicine, clinical pharmacology, restoring therapy.

SUBSTANCE: the suggested preparation is being a lipid fraction isolated out of a king crab's liver Paralithodes comtschatica that contains 10% polyunsaturated fatty acids, 10% alkyl-diacyl glycerides and the complex of natural bioantioxidants being of highly correcting, hypocoagulative and antioxidant properties. The preparation suggested enables to widen the quantity of food BAA of natural origin of lipid-correcting action at pronounced hypocoagulative and antioxidant properties based upon application of natural lipid complex. It could be applied as an efficient means of prophylaxis of cardio-vascular diseases and other pathologies, when lipid exchange is broken and which is accompanied with disorders of hemocoagulation and intensification of lipoperoxidation process.

EFFECT: higher efficiency.

1 ex, 4 tbl

FIELD: biologically active substances, medicine.

SUBSTANCE: claimed agent for parantheral administration represents peptide complex containing 70-90 % of low molecular fraction comprising peptide components with molecular mass 70-184 Da, and peptide concentration of 2.5-2.9 mg/ml. Said agent is obtained from liver of calf not older than 12 months or hog by extraction with acetic acid in presence of zinc chloride. Calf or hog liver are frozen at not less -40°C, conditioned at -20-22°C for at least two months, and ground. Then 3 % acetic acid solution in volume ratio of 1:5 is added at 20±5°C. Extraction is carried out under continuous stirring to produce homogenous slurry. Then 1 % zinc chloride solution is added into slurry in volume ratio of 50:1; mixture is cooled under continuous stirring to 7-16°C; stirred during 1 h after each 4 h defecation for 48 hours. Extract is separated from ballast substances; acetone is added to extract in volume ratio of 1:5, followed by conditioning at 3-5°C for 4 hours. Obtained homogenized deposition is deposited again with acetone two time or more. Further active substance containing precipitate is washed on gravity filter with two-fold volumes of acetone cooled to 7-16°C to produce light-gray precipitate. Precipitate is passed through metal sieve, dried, dissolved in distilled water at room temperature and continuous stirring to produce polypeptide concentration of 2.5-2.9 mg/ml. Solution is centrifuged, filtered, subjected to ultrafiltration purification under back pressure of 1.0 kgf/cm2 or less trough materials with retentiveness of 15000 Da. Glycocol is added into ultrafiltrate up to finish concentration of 10-20 mg/mg at pH 5.6-6.6. Solution is subjected to sterilizing filtration under pressure of 2.0 kgf/cm2 or less, poured in 2 ml ampoules, and autoclaved for 8 min, at 120°C and atmospheric pressure of 1.1 kgf/cm2.

EFFECT: method of increased yield, non-toxic and apirogenic agent of improved purity.

2 cl, 5 ex, 4 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing bio-organic preparation into patient organism. The preparation is introduced at a daily dose of 2 ml intramuscularly during 3-4 weeks.

EFFECT: enhanced effectiveness of treatment.

2 dwg

FIELD: veterinary medicine.

SUBSTANCE: the present innovation deals with methods to activate the activity of protective mechanisms and organs of hormonal regulations. One should introduce a tissue preparation for an animal, moreover, to obtain it is necessary to apply 2.5 g pregnant or postpartum uterus, per 1.5 g thyroid, parathyroid and thymus glands, 2.0 g pancreas, 2.5 g liver all purified against spare tissues from clinically and hematologically healthy animals from cattle group up to 4-6-yr-aged period. The organs mentioned should be reduced, then tissue mixture obtained should be mixed with fresh running water at 1:2 ratio to obtain emulsion to be thermally treated in water bath at 58-59 C. After cooling emulsion should be supplemented with formalin, ACD f-2 and natural bee honey to obtain the following ratio of components in ready-to-use product: tissue emulsion 10 g, 68.7%; ACD f-2 1.5 g, 10.3%; formalin 0.006 g, 0.4%; natural bee honey 3.0 g, 20.6%. Before being introduced for an animal one should carefully mix preparation to detect its dosage at 0.02-0.5 ml/kg animal body weight to be then introduced per Ѕ parts from the right and from the left into dorsal lumbar muscles either once or twice at interval of 7-9 d. The method enables to perform complex biostimulating and hormonal impact upon animal body due to keeping active substances of tissue preparation being obtained due to above-mentioned technique.

EFFECT: higher efficiency of prophylaxis and therapy.

FIELD: agriculture, veterinary science.

SUBSTANCE: the present innovation deals with normalizing the flow of coupling, mating and lambing, the rate of growth for preventing and treating acute and chronic diseases of etiology in animals. One should prepare a tissue preparation due to applying cow's ovaries without yellow bodies, thyroid and parathyroid glands, thymus, pancreas and liver of cattle up to 4-yr-aged terms. The organs mentioned should be separately kept for 9-10 d in a fridge to be separately reduced thrice with a meat chopper, diluted with fresh running water at 1:2 ratio, extracted for 4 h in glassware at room temperature, thoroughly mixed every 10-15 min, treated in water bath for 1 h at 58-59 C, separately filtered through double-layered sterile gauze to keep a filtrate 4 times at 1-d-long interval in water bath at 58-59 C for 1 h. Components should be mixed so, that their ratio in preparation should be, weight%: ovarian tissue emulsion 10.3, thyroid and parathyroid emulsion 10.3, that of thymus 10.3, that of pancreas 17.2, that of liver 20.6, ACD f-2 10.3, formalin 0.4, natural bee honey 20.6. Before injection the preparation should be mixed and introduced per 1/2 dosage into dorsal lumbar muscles at 0.02-0.04 ml/kg animal body weight. The innovation provides complex biostimulation, activation of hormonal regulation of animal body.

EFFECT: higher efficiency of prophylaxis and therapy.

1 tbl

FIELD: medicine.

SUBSTANCE: device has Dacron sack usable as envelope introducible into soft tissues of the head. The envelope has two 0.5 mm thick liver tissue leaflets between which hypothalamus tissue leaflets taken from young animal brain and black substance or isolated suprarenal gland medullary substance cells or that of human glands or the like cells taken from human embryo. The Dacron envelope is 25-30 cm long, 5 mm wide and 2 mm thick.

EFFECT: enhanced effectiveness of treatment.

2 cl, 1 dwg

FIELD: medicine, hepatology, chemical-pharmaceutical industry, biotechnology.

SUBSTANCE: invention relates to a biotransplant used in treatment of chronic hepatitis and liver cirrhosis and comprising mesenchymal stem cells obtained from fetal or donor material. The parent tissue is subjected for disaggregation followed by culturing as fixed colonies in the growth medium containing fetal calve serum and glutamine and passage at low density value with change of medium composition and cultivation is carried out without accumulation cells with mature stroma in culture. Also, invention relates to a method for treatment of chronic hepatitis and liver cirrhosis that involves administration of indicated biotransplants by using venous catheter or by puncture in the portal system veins, or by using arterial catheter in splenic artery, or by puncture in spleen parenchyma, or by intraperitoneal route, or by puncture in gastrocolic omentum. Invention provides enhancing effectiveness in complex effect on damaged liver.

EFFECT: improved preparing method, improved treatment method.

13 cl

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with freezing the tissues of animal parenchymatous organs followed by defrosting, homogenization and hydrolysis. Hydrolysis should be conducted at the presence of succinic acid at pH being -4.0 and 45°C. Hydrolyzate should be decanted followed by addition of 3%-caustic soda solution up to pH=7.0; moreover, it is necessary to add novocain powder to hydrolyzate up to 0.4-0.5% concentration and gel of aluminium oxide hydrate at 2-3 mg/ml. The preparation obtained should be packed into 50-ml vials to be sterilized due to autoclaving at the mode of 1.0 atm. for 20 min. The innovation provides less reactogenic final product of prolonged action and increased anti-infectious activity.

EFFECT: higher efficiency.

2 ex, 2 tbl

FIELD: medicine, biochemistry.

SUBSTANCE: claimed method includes administration of uricase solution into at least one separation column at pH approximately 9-10,5 and reduction from the said column of one or more fractions containing isolated tetra-dimensional urecase aggregate-free uricase, wherein tetra-dimensional urecase aggregates are larger than tetra-dimensional urecase.

EFFECT: 9 cl, 12 ex, 13 dwg.

FIELD: medicine, peptides.

SUBSTANCE: invention relates to a method for preparing a peptide complex from animal raw possessing the tissue-specific activity. Method for preparing an agent for maintaining therapy possessing tissue-specific activity involves milling calf or pig organs of age 12 months, not above, addition of 3% acetic acid solution at temperature 20 ± 5°C and extraction is carried out at constant stirring. Then, in 30 min zinc chloride 1% solution is added, mixture is cooled to temperature 7-16°C at constant stirring followed by stirring for every 1 h in each 4 h and settling for 48 h. Extract is separated from inert substances by separation and acetone is added to extract in the volume ratio = 1:5, mixture is kept at 3-5°C for 4 h and formed precipitate is washed out with out with two-fold volume of acetone cooled to temperature 7-16°C, formed precipitate is rubbed through a metallic sieve and prepared end product is dried at temperature 18 ± 2°C. The end product represents a peptide complex with the content of low-molecular peptide fraction from 70% to 90% and with molecular mass of its peptide components in the range 1000-12000 Da wherein this complex comprises amino acids, mineral substances, trace elements and vitamins in biologically bound form. The complex elicits the expressed tissue-specific activity based on the proposed sequence of technological procedures and conditions for their realization involving temperature, temporal and other indices, and by using substances including the parent raw, a definite extractant and others. Peptide component in the prepared complex has no denaturating properties and retains its regulatory properties that suggests its using as an agent for carrying out the maintaining therapy. The proposed agent can be used in medicinal practice as an agent used in carrying out the maintaining therapy.

EFFECT: improved preparing method, valuable medicinal properties of agent.

9 cl, 42 tbl, 14 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to the development of a medicament used in carrying out the supporting therapy in metabolism disturbance caused by increased blood cholesterol and made as a tablet. Agent is proposed as two tablets taken in different times. "Litokhol" enhances bile solubility effectively, inhibits formation of cholesterol crystals and stones. Also, it doesn't inhibit cholesterol biosynthesis in hepatocytes and its excesses are removed from body being without its slagging and doing reasons for development of systemic complications.

EFFECT: valuable medicinal property of agent.

7 cl

FIELD: biologically active substances, medicine.

SUBSTANCE: claimed agent for parantheral administration represents peptide complex containing 70-90 % of low molecular fraction comprising peptide components with molecular mass 70-184 Da, and peptide concentration of 2.5-2.9 mg/ml. Said agent is obtained from liver of calf not older than 12 months or hog by extraction with acetic acid in presence of zinc chloride. Calf or hog liver are frozen at not less -40°C, conditioned at -20-22°C for at least two months, and ground. Then 3 % acetic acid solution in volume ratio of 1:5 is added at 20±5°C. Extraction is carried out under continuous stirring to produce homogenous slurry. Then 1 % zinc chloride solution is added into slurry in volume ratio of 50:1; mixture is cooled under continuous stirring to 7-16°C; stirred during 1 h after each 4 h defecation for 48 hours. Extract is separated from ballast substances; acetone is added to extract in volume ratio of 1:5, followed by conditioning at 3-5°C for 4 hours. Obtained homogenized deposition is deposited again with acetone two time or more. Further active substance containing precipitate is washed on gravity filter with two-fold volumes of acetone cooled to 7-16°C to produce light-gray precipitate. Precipitate is passed through metal sieve, dried, dissolved in distilled water at room temperature and continuous stirring to produce polypeptide concentration of 2.5-2.9 mg/ml. Solution is centrifuged, filtered, subjected to ultrafiltration purification under back pressure of 1.0 kgf/cm2 or less trough materials with retentiveness of 15000 Da. Glycocol is added into ultrafiltrate up to finish concentration of 10-20 mg/mg at pH 5.6-6.6. Solution is subjected to sterilizing filtration under pressure of 2.0 kgf/cm2 or less, poured in 2 ml ampoules, and autoclaved for 8 min, at 120°C and atmospheric pressure of 1.1 kgf/cm2.

EFFECT: method of increased yield, non-toxic and apirogenic agent of improved purity.

2 cl, 5 ex, 4 tbl, 1 dwg

Up!